Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 50
Filter
1.
bioRxiv ; 2024 Jun 13.
Article in English | MEDLINE | ID: mdl-38915593

ABSTRACT

Flavin-containing monooxygenases (FMOs) are a conserved family of xenobiotic enzymes upregulated in multiple longevity interventions, including nematode and mouse models. Previous work supports that C. elegans fmo-2 promotes longevity, stress resistance, and healthspan by rewiring endogenous metabolism. However, there are five C. elegans FMOs and five mammalian FMOs, and it is not known whether promoting longevity and health benefits is a conserved role of this gene family. Here, we report that expression of C. elegans fmo-4 promotes lifespan extension and paraquat stress resistance downstream of both dietary restriction and inhibition of mTOR. We find that overexpression of fmo-4 in just the hypodermis is sufficient for these benefits, and that this expression significantly modifies the transcriptome. By analyzing changes in gene expression, we find that genes related to calcium signaling are significantly altered downstream of fmo-4 expression. Highlighting the importance of calcium homeostasis in this pathway, fmo-4 overexpressing animals are sensitive to thapsigargin, an ER stressor that inhibits calcium flux from the cytosol to the ER lumen. This calcium/ fmo-4 interaction is solidified by data showing that modulating intracellular calcium with either small molecules or genetics can change expression of fmo-4 and/or interact with fmo-4 to affect lifespan and stress resistance. Further analysis supports a pathway where fmo-4 modulates calcium homeostasis downstream of activating transcription factor-6 ( atf-6 ), whose knockdown induces and requires fmo-4 expression. Together, our data identify fmo-4 as a longevity- promoting gene whose actions interact with known longevity pathways and calcium homeostasis.

2.
Acta Neurol Scand ; 117(4): 266-72, 2008 Apr.
Article in English | MEDLINE | ID: mdl-17922888

ABSTRACT

OBJECTIVES: Hereditary neuropathy with liability to pressure palsies (HNPP) is an inherited disorder resulting in a polyneuropathy with particular involvement at sites of entrapment, and is often underdiagnosed or misdiagnosed. We report findings on seven patients referred for evaluation of focal mononeuropathies or polyneuropathies of undetermined etiology, in whom we established a diagnosis of HNPP. MATERIALS AND METHODS: We retrospectively reviewed clinical, electrophysiological and laboratory data for patients diagnosed with HNPP over a 4-year period at our institution. RESULTS: All patients had transient or recurrent neurological symptoms, some with residual deficits. No patients had a family history of any neuropathy. Electrodiagnostic studies revealed abnormal conduction findings at symptomatic and asymptomatic sites. Testing for the Peripheral Myelin Protein (PMP22) deletion was positive in all patients. CONCLUSIONS: A high index of clinical suspicion and thorough electrodiagnostic evaluation can lead to correct diagnosis of HNPP, despite the absence of a positive family history.


Subject(s)
Heredodegenerative Disorders, Nervous System/diagnosis , Heredodegenerative Disorders, Nervous System/physiopathology , Peripheral Nerves/physiopathology , Peripheral Nervous System Diseases/diagnosis , Peripheral Nervous System Diseases/physiopathology , Action Potentials/genetics , Adolescent , Adult , DNA Mutational Analysis , Diagnosis, Differential , Electrodiagnosis/methods , Female , Genetic Markers/genetics , Genetic Testing , Genotype , Heredodegenerative Disorders, Nervous System/genetics , Humans , Male , Middle Aged , Muscle Weakness/diagnosis , Muscle Weakness/genetics , Muscle Weakness/physiopathology , Muscle, Skeletal/innervation , Muscle, Skeletal/physiopathology , Muscular Atrophy/diagnosis , Muscular Atrophy/genetics , Muscular Atrophy/physiopathology , Myelin Proteins/genetics , Neural Conduction/genetics , Paresthesia/diagnosis , Paresthesia/genetics , Paresthesia/physiopathology , Peripheral Nervous System Diseases/genetics , Predictive Value of Tests , Retrospective Studies
3.
Acta Neurol Scand ; 115(4): 284-8, 2007 Apr.
Article in English | MEDLINE | ID: mdl-17286624

ABSTRACT

BACKGROUND: Painful diabetic neuropathy is a common complication of diabetes and often resistant to treatment with standard analgesics. Treatment of diabetic neuropathy with antiepileptic drugs may provide pain relief. AIM: To evaluate the long-term safety and tolerability of oxcarbazepine in two studies investigating the treatment of diabetic neuropathy. OBJECTIVES: Patients with diabetes and a history of neuropathic pain were included. Study 1 was a multicenter, open-label study comprising a screening and 12-month treatment phase. Study 2 was a multicenter, open-label extension to a double-blind, randomized study. Oxcarbazepine was initiated at 300 mg/day and titrated over 4 weeks to tolerability or a maximum dose of 900 mg b.i.d. Safety was assessed by monitoring adverse events (AEs), serious AEs (SAEs), hematology, blood chemistry, urinalysis values, and vital signs. RESULTS: Adverse events were most frequently reported in the nervous and gastrointestinal systems; 20.5% and 21.6% of patients withdrew because of AEs in study 1 and study 2, respectively. SAEs were reported in 13.7% and 14.4% of patients in study 1 and study 2, respectively. CONCLUSIONS: Long-term treatment with oxcarbazepine is generally well tolerated in patients with painful diabetic neuropathy. Rapid titration of oxcarbazepine may be responsible for discontinuations resulting from AEs during early stages of treatment.


Subject(s)
Anticonvulsants/administration & dosage , Carbamazepine/analogs & derivatives , Diabetic Neuropathies/drug therapy , Adult , Aged , Anticonvulsants/adverse effects , Carbamazepine/administration & dosage , Carbamazepine/adverse effects , Double-Blind Method , Drug Administration Schedule , Female , Follow-Up Studies , Humans , Male , Middle Aged , Oxcarbazepine , Pain Measurement , Treatment Outcome
4.
Blood Coagul Fibrinolysis ; 13(2): 123-8, 2002 Mar.
Article in English | MEDLINE | ID: mdl-11914654

ABSTRACT

The enhanced extrinsic coagulation in response to inflammation could contribute to disseminated intravascular coagulation, often manifesting cardiovascular complications. The complex mechanism remains unclear. Nor is the effective anticoagulation well established. The search for arresting hypercoagulation is of antithrombotic relevance. The ability of polybrene (PB) to inhibit tissue factor (TF)-initiated extrinsic blood coagulation was demonstrated at the protein and cellular levels as well as in human plasma samples. In a single-stage clotting assay, PB dose-dependently offset bacterial endotoxin (lipopolysaccharide)-induced monocytic TF (mTF) hypercoagulation and inhibited rabbit brain thromboplastin (rbTF) procoagulation. Consistent with these findings, the significantly prolonged prothrombin time indicated the depressed extrinsic coagulation by PB. However, PB showed no effect on thrombin time. We dissected the extrinsic pathway to further determine the inhibitory site(s) of PB. A two-stage chromogenic assay monitoring S-2288 hydrolysis showed that PB readily blocked mTF-dependent or rbTF-dependent FVII activation, which was verified by the diminished activated factor VII (FVIIa) formation derived from the proteolytic cleavage of its zymogen factor VII on Western blotting analyses. PB had no effect on FVIIa and activated factor X amidolytic activity. Nor was the dissected TF/FVIIa-catalyzed factor X activation affected. In conclusion, the preferential downregulation of factor VII activation was responsible for the depressed extrinsic coagulation. PB could present a novel anticoagulant antagonizing the extrinsic hypercoagulation for the prevention of thrombotic complication following sepsis and inflammations.


Subject(s)
Anticoagulants/pharmacology , Endotoxins/pharmacology , Hexadimethrine Bromide/pharmacology , Thrombophilia/prevention & control , Thromboplastin/antagonists & inhibitors , Blood Coagulation/drug effects , Dose-Response Relationship, Drug , Drug Antagonism , Factor VIII/antagonists & inhibitors , Factor VIII/metabolism , Humans , Lipopolysaccharides/pharmacology , Monocytes/metabolism , Thrombophilia/etiology , Tumor Cells, Cultured
5.
Br J Haematol ; 115(2): 392-9, 2001 Nov.
Article in English | MEDLINE | ID: mdl-11703341

ABSTRACT

The enhanced extrinsic coagulation in response to inflammation could contribute to disseminated intravascular coagulation, often manifesting cardiovascular complications. The complex mechanism remains unclear and effective management is not well established. The ability of protamine to offset bacterial endotoxin (LPS)-induced tissue factor (TF)-initiated extrinsic coagulation was demonstrated in human peripheral blood monocytes and cultured human leukaemia THP-1 monocytes, which was consistent with the inhibition of rabbit brain thromboplastin (rbTF) procoagulant activity in a cell-free in vitro model. Protamine significantly prolonged prothrombin time, further confirming the downregulation of the extrinsic pathway. However, thrombin time remained unaltered. Chromogenic assays were performed to dissect the extrinsic pathway, identifying inhibitory site(s). Protamine significantly inhibited factor VII (FVII) activation but not the dissected FX activation. The amidolytic activities of FVIIa and FXa were unaffected. The inhibited FVII activation in the presence of protamine was confirmed by the diminished FVIIa formation on Western blot analyses. Protamine preferentially inhibited TF-catalysed FVII activation, downregulating the extrinsic cascade. Protamine could be of anticoagulant significance in the management of the extrinsic hypercoagulation.


Subject(s)
Anticoagulants/pharmacology , Blood Coagulation/drug effects , Protamines/pharmacology , Thromboplastin/antagonists & inhibitors , Cell Culture Techniques , Factor VIIa/metabolism , Factor X/metabolism , Humans , Lipopolysaccharides/pharmacology , Monocytes/drug effects , Monocytes/physiology , Prothrombin Time , Thrombin Time , Thromboplastin/pharmacology
6.
Muscle Nerve ; 24(10): 1396-402, 2001 Oct.
Article in English | MEDLINE | ID: mdl-11562923

ABSTRACT

Multifocal motor neuropathy (MMN) is a disorder of peripheral nerve often associated with a high monosialoganglioside (GM1) antibody and multifocal conduction block. It has a chronic, indolent course with involvement of predominantly peripheral motor nerves, usually in an asymmetric fashion. There have been few reported cases of progression to frank quadriplegia. Secondary amyloidosis refers to the deposition of amyloid in various tissues due to an underlying chronic inflammatory state. We report the first case, to our knowledge, of a patient with MMN associated with high titer of GM1 antibody who developed acute paraplegia with both cranial nerve and worsening sensory involvement associated with multiorgan compromise due to a secondary amyloidosis involving the myocardium.


Subject(s)
Amyloidosis/pathology , Motor Neuron Disease/pathology , Amyloidosis/etiology , Autoantibodies/blood , Fatal Outcome , Femoral Nerve/pathology , G(M1) Ganglioside/immunology , Humans , Male , Median Nerve/physiopathology , Middle Aged , Motor Neuron Disease/complications , Motor Neuron Disease/physiopathology , Neural Conduction , Tibial Nerve/physiopathology , Ulnar Nerve/physiopathology
7.
Arch Biochem Biophys ; 392(1): 3-7, 2001 Aug 01.
Article in English | MEDLINE | ID: mdl-11469787

ABSTRACT

The enhanced extrinsic blood coagulation following septic shock often manifests cardiovascular complications. The upregulated monocytic tissue factor (mTF) was shown to be a primary contributor to the extrinsic hypercoagulation following acute bacterial endotoxin (LPS) infection. A single-stage clotting assay monitors TF-initiated coagulation. We herein demonstrate a novel anticoagulant activity of antimicrobial peptide Buforin I (BF I) in offsetting LPS-induced mTF hypercoagulation in THP-1 cells, which was confirmed in a cell-free in vitro model, showing that BF I effectively blocked rabbit brain thromboplastin (rbTF) procoagulant activity. Upon inclusion of 25 microM BF I into human plasma, the prolonged prothrombin time (PT) was consistent with the depressed TF-initiated coagulation. In a two-stage chromogenic assay monitoring S-2288 hydrolysis, BF I significantly inhibited not only mTF- but also rbTF-catalyzed FVII activation accompanied by the diminished FVIIa formation. The inhibition by BF I of FVII activation accounted for its novel anticoagulant activity in offsetting mTF-initiated hypercoagulation.


Subject(s)
Anti-Infective Agents/pharmacology , Blood Coagulation/drug effects , Proteins/pharmacology , Thromboplastin/antagonists & inhibitors , Amino Acid Sequence , Animals , Anti-Infective Agents/chemistry , Cell Line , Factor VII/metabolism , Humans , In Vitro Techniques , Lipopolysaccharides/toxicity , Molecular Sequence Data , Proteins/chemistry , Rabbits , Shock, Septic/blood , Shock, Septic/complications , Thrombosis/blood , Thrombosis/drug therapy , Thrombosis/etiology
8.
Br J Pharmacol ; 133(5): 659-64, 2001 Jul.
Article in English | MEDLINE | ID: mdl-11429389

ABSTRACT

The ability of ruthenium red (RuR) to inhibit tissue factor (TF)-initiated blood coagulation was demonstrated at the protein and cellular levels as well as in human plasma. In a single-stage clotting assay, RuR concentration-dependently inhibited rabbit brain thromboplastin (rbTF)-induced coagulation and offset bacterial endotoxin (LPS)-induced monocytic TF (mTF) hypercoagulation; the IC(50)s were estimated at 7.5 and 12.3 microM, respectively. A 15-min preincubation of RuR with rbTF or monocyte suspension resulted in the pronounced inhibition with a significantly lowered IC(50) at 1.8 or 7.7 microM for rbTF or mTF procoagulation, respectively. The differences in IC(50)s between rbTF and mTF without or with the preincubation indicated that TF was a primary target for RuR action. The effect of RuR on the physiological function of TF in FVII activation was demonstrated by the proteolytic cleavage of FVII zymogen to its active forms of serine protease on Western blotting analyses. RuR readily blocked TF-catalyzed FVII activation (diminished FVIIa formation), thus down regulating the initiation of blood coagulation. Inclusion of RuR into human plasma samples in vitro significantly prolonged prothrombin time, indicating the depressed coagulation. FVII activity was inhibited by 30 - 60% depending on the dose; as a result, FX activity also decreased. However, RuR showed no effect on thrombin time. Thus, RuR inhibited FVII activation to block the initiation of coagulation.


Subject(s)
Blood Coagulation/drug effects , Ruthenium Red/pharmacology , Thromboplastin/pharmacology , Dose-Response Relationship, Drug , Down-Regulation , Factor VII/drug effects , Factor VII/metabolism , Factor VIIa/drug effects , Factor VIIa/metabolism , Humans , Lipopolysaccharides/pharmacology , Tumor Cells, Cultured
10.
Muscle Nerve ; 23(4): 556-9, 2000 Apr.
Article in English | MEDLINE | ID: mdl-10716767

ABSTRACT

Diaphragmatic paralysis has previously been reported as a result of diverse pathologic processes involving the peripheral nervous system. We report the clinical history, physical findings, and antibody profile of an atypical case of multifocal motor neuropathy with conduction block initially presenting with respiratory failure secondary to bilateral phrenic neuropathy.


Subject(s)
Motor Neuron Disease/diagnosis , Neural Conduction/physiology , Paralysis/etiology , Peripheral Nervous System Diseases/diagnosis , Peripheral Nervous System Diseases/physiopathology , Phrenic Nerve , Aged , Diaphragm , Functional Laterality , Humans , Male , Median Nerve/physiopathology , Motor Neuron Disease/etiology , Peroneal Nerve/physiopathology , Tibial Nerve/physiopathology , Ulnar Nerve/physiopathology
11.
J Surg Res ; 87(2): 252-7, 1999 Dec.
Article in English | MEDLINE | ID: mdl-10600357

ABSTRACT

BACKGROUND: Hypercoagulability is one of the commonly exhibited endotoxemia septic symptoms; it could contribute to the manifestation of disseminated intravascular coagulation presenting threats to cardiovascular functions. The underlying mechanism, however, remains largely complex and unknown. OBJECTIVES: We herein determine whether bacterial endotoxin (LPS) upregulates the activities of clotting factors in plasma, contributing to extrinsic hypercoagulation. Compound 48/80 (48/80) is also tested for its ability to suppress hypercoagulation. METHODS: In an in vitro infection model, we exposed whole blood to LPS (Escherichia coli 0111:B04; 100 ng/ml) for 2 h. Thrombin time (TT), prothrombin time (PT), and the activities of clotting factors ( FVII, FIX, FX ) in plasma contributing to the extrinsic coagulation were determined. Peripheral blood monocytes were isolated from Histoplaque 1077 gradient centrifugation, and the procoagulant activity was determined by a single-stage clotting assay on a Fibrometer. RESULTS: LPS drastically activated monocytic procoagulant activity which was defined as tissue factor (TF) activity, whereas LPS had no effect on TT, PT, and the activities of clotting factors in plasma. 48/80 not only instantaneously offset LPS-induced monocytic TF activation, but also significantly inhibited PT including the activities of clotting factors (FVII, FIX, and FX) in plasma, whereas TT remained unaffected. CONCLUSIONS: Monocytic TF activation was solely responsible for the extrinsic hypercoagulation in response to LPS. 48/80 effectively suppressed LPS-induced monocyticTF-initiated extrinsic coagulation at multiple sites, possibly presenting a new therapy for an instantaneous relief of hypercoagulation under septic conditions.


Subject(s)
Blood Coagulation/drug effects , Lipopolysaccharides/toxicity , Monocytes/physiology , Thromboplastin/physiology , p-Methoxy-N-methylphenethylamine/pharmacology , Factor VII/physiology , Factor X/physiology , Humans
12.
J Matern Fetal Med ; 8(3): 114-8, 1999.
Article in English | MEDLINE | ID: mdl-10338065

ABSTRACT

OBJECTIVES: The objective of this study was to compare the efficacy and safety of two dosing regimens of misoprostol for cervical ripening and labor induction. METHODS: Patients who fulfilled the study criteria were randomized to received misoprostol 25 microg or 50 microg intravaginally every 3 h for a total of eight doses for cervical ripening or until labor was established. Endpoints for successful cervical ripening was achievement of Bishop score of nine or greater, and for labor induction reaching the active phase of labor in the first 24 h. The rates of success, duration of first and second stages of labor, type of delivery, significant side effects, and neonatal outcome were measured and compared between the two study groups. Two hundred and fifty-one patients were randomized in two groups--126 received 50 microg and 125 received 25 microg misoprostol. Demographics of the two study groups were similar. RESULTS: Patients in the 50 microg group had a shorter first stage (848 min vs. 1,122 min, P < 0.007), shorter induction-to-vaginal delivery interval (933 min vs. 1,194 min, P < 0.013), decreased incidence of oxytocin augmentation (53.9% vs. 68%, P < 0.015), and decreased total units of oxytocin (2,763 mU vs. 5,236 mU, P < 0.023), but there was a higher hyperstimulation rate (19% vs. 7.2%, P < 0.005). CONCLUSIONS: Successful induction rate, delivery types, and fetal outcome were similar in both groups. Although the rate of vaginal delivery and neonatal outcome were similar in both groups, the 50 microg regimen had shorter first and second stages of labor, and a higher hyperstimulation rate that was easily manageable, allowing for flexibility in using the higher dose in low-risk pregnancies.


Subject(s)
Cervix Uteri/physiology , Labor, Induced , Misoprostol/administration & dosage , Oxytocics/administration & dosage , Adult , Cesarean Section , Double-Blind Method , Female , Heart Rate, Fetal , Humans , Misoprostol/adverse effects , Misoprostol/therapeutic use , Oxytocics/adverse effects , Oxytocics/therapeutic use , Pregnancy , Pregnancy Outcome
13.
Am J Obstet Gynecol ; 179(5): 1210-3, 1998 Nov.
Article in English | MEDLINE | ID: mdl-9822502

ABSTRACT

OBJECTIVES: The study's objectives were as follows: (1) to determine the rate of vaginal delivery after labor induction in severe preeclampsia remote from term and (2) to determine potential predictors of success. STUDY DESIGN: Retrospective chart review was conducted on live-born singleton pregnancies complicated by severe preeclampsia and delivered at 24 to 34 weeks' gestation from January 1, 1992, to December 31, 1996. Exclusion criteria included eclampsia, presence of labor or spontaneous rupture of membranes on admission, and complication of pregnancy by an ultrasonographically detected fetal congenital anomaly. Patients were divided into 3 groups: elective cesarean delivery without labor, cesarean delivery after labor induction, and vaginal delivery after labor induction. Statistical analyses included multiple logistic regression, the Student t test, the chi2 test, and the Mann-Whitney test. P 32 weeks' gestation. The most common indication for cesarean delivery after induction, in 50.7% of the cases, was nonreassuring fetal heart rate. The median Bishop score was significantly higher (3 vs 2, P =.004) and the total hospital stay was significantly shorter in the vaginal delivery after induction group than in the cesarean delivery after induction group. However, there were no significant differences between the 2 groups in use of cervical ripening agents, gestational age at delivery, birth weight, 5-minute Apgar score, or postpartum endometritis. After exclusion of cesarean deliveries performed for malpresentation, there was no statistically significant difference in classic incision rates between the elective cesarean delivery without labor and cesarean delivery after induction groups (13.6% vs 6.8%; P =.137). According to logistic regression analysis, only the Bishop score was significantly associated with a successful induction (odds ratio 1.38, 95% confidence interval 1.11-1.71). Gestational age reached marginal significance (odds ratio 1.30, 95% confidence interval 0.89-1.89). CONCLUSIONS: (1) Labor induction should be considered a reasonable option for patients with severe preeclampsia at

Subject(s)
Cesarean Section , Delivery, Obstetric , Labor, Induced , Pre-Eclampsia/physiopathology , Adult , Delivery, Obstetric/methods , Female , Gestational Age , Humans , Infant, Newborn , Infant, Premature , Medical Records , Pregnancy , Retrospective Studies , Time Factors
14.
Muscle Nerve ; 21(6): 813-5, 1998 Jun.
Article in English | MEDLINE | ID: mdl-9585340

ABSTRACT

We describe a 58-year-old male with a few years history of multifocal weakness in the upper limbs with minimal to absent sensory complaints. He was diagnosed as having multiple compressive neuropathies, which required repeated decompressive surgeries. Electrodiagnostic studies prior to diagnosis were limited to a few nerves, evaluating only distal segments. Because of delay in making the diagnosis, his condition progressed, and possibly because of the unnecessary surgeries, he developed atrophy in some muscles, which resulted in significant motor disability. He was later diagnosed as having multifocal motor neuropathy with conduction block and has partially responded to intravenous immunoglobulin therapy.


Subject(s)
Motor Neuron Disease/diagnosis , Nerve Compression Syndromes/diagnosis , Neural Conduction , Atrophy , Diagnostic Errors , Humans , Immunization, Passive , Injections, Intravenous , Male , Middle Aged , Motor Neuron Disease/therapy , Muscle, Skeletal/pathology , Nerve Compression Syndromes/surgery
16.
Am J Obstet Gynecol ; 173(4): 1263-6, 1995 Oct.
Article in English | MEDLINE | ID: mdl-7485334

ABSTRACT

OBJECTIVE: Our purpose was to determine the degree of fetal pyelectasis predictive of neonatal renal pathologic processes. STUDY DESIGN: Eighty-four cases of pyelectasis were identified during the study period (1989 through 1993). Fetuses with anteroposterior diameter of the renal pelvis > or = 4 mm before 33 weeks or > or = 7 mm after 33 weeks without caliectasis were included. Fetuses with an anteroposterior diameter of > 10 mm were excluded. Postnatal evaluation included renal sonogram, voiding cystourethrogram, and renal flow and function studies. RESULTS: Sixteen cases were excluded because of incomplete postnatal workup. Renal pathologic processes were found in 30 of 68 (44%) at birth; the most common were ureteropelvic junction obstruction (37%) and vesicoureteral reflux (33%). Only four cases required surgical intervention (13%), and the remaining 87% were managed conservatively. A normal urinary tract was found in 25% of the infants and the remaining 21 of 68 (31%) had regression of pyelectasis before birth. Fetuses with a dilated anteroposterior diameter > or = 8 mm after 28 weeks' gestation were found to have renal pathologic features in two of three of the cases, with sensitivity, specificity, and positive and negative predictive values of 87%, 41%, 66.7% and 70%, respectively. CONCLUSION: Fetuses with an anteroposterior diameter of the renal pelvis > or = 8 mm after 28 weeks' gestation require appropriate urologic evaluation after birth.


Subject(s)
Fetal Diseases/diagnostic imaging , Kidney Diseases/diagnostic imaging , Dilatation, Pathologic/diagnostic imaging , Female , Humans , Infant, Newborn , Kidney Pelvis , Male , Predictive Value of Tests , Pregnancy , Sensitivity and Specificity , Ultrasonography, Prenatal , Ureteral Obstruction/diagnostic imaging , Vesico-Ureteral Reflux/diagnostic imaging
SELECTION OF CITATIONS
SEARCH DETAIL
...